Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.250-2.550 for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

Analysts Set New Price Targets

Several research firms have issued reports on PRGO. Argus raised Perrigo to a “hold” rating in a research note on Wednesday, January 14th. Canaccord Genuity Group dropped their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Finally, Weiss Ratings cut shares of Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Stock Down 0.4%

NYSE:PRGO traded down $0.06 on Thursday, hitting $12.21. 609,726 shares of the company’s stock were exchanged, compared to its average volume of 3,028,364. The firm has a 50-day moving average price of $11.05 and a 200-day moving average price of $13.66. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63. Perrigo has a 52 week low of $9.23 and a 52 week high of $28.43. The company has a market cap of $1.68 billion, a P/E ratio of -1.19, a price-to-earnings-growth ratio of 1.37 and a beta of 0.52.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The firm had revenue of $841.80 million for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the previous year, the firm posted $0.60 EPS. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, analysts expect that Perrigo will post 2.12 EPS for the current fiscal year.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th will be issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 9.5%. The ex-dividend date of this dividend is Friday, May 29th. Perrigo’s dividend payout ratio is presently -11.28%.

Institutional Investors Weigh In On Perrigo

Institutional investors and hedge funds have recently modified their holdings of the company. Geneos Wealth Management Inc. raised its holdings in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after purchasing an additional 786 shares during the period. Kestra Investment Management LLC raised its holdings in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares during the period. UMB Bank n.a. raised its holdings in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock valued at $27,000 after purchasing an additional 1,213 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Perrigo in the 4th quarter valued at about $28,000. Finally, Danske Bank A S bought a new stake in shares of Perrigo in the 3rd quarter valued at about $53,000. 95.91% of the stock is owned by institutional investors.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.